Company / Cash & Equivalents
Ernexa Therapeutics Inc. Cash & Equivalents History
FY2014-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.6M
FY2023
5-year range
$3.2M / $7.6M
FY2019-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 7 years, ranging from $3M in FY2018 to $8M in FY2023.
Based on SEC 10-K filings.
$8M in FY2023 with a 5-year CAGR of +24.5%.
Improved from $3M to $8M over the past 5 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +24.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +24.5%, indicating consistent growth.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $7.6M | - |
| FY2020 | - | - |
| FY2019 | $3.2M | +26.5% |
| FY2018 | $2.5M | -55.4% |
| FY2017 | $5.7M | +76.4% |
| FY2016 | $3.2M | -55.1% |
| FY2015 | $7.2M | +31.7% |
| FY2014 | $5.5M | +100.5% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026